Drug Profile
Imatinib inhalation - Aerami Therapeutics
Alternative Names: AER-901; Inhaled imatinib - Aerami Therapeutics; VR-325Latest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Vectura
- Developer Aerami Therapeutics
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor receptor antagonists; Proto oncogene protein c-kit inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Pulmonary arterial hypertension; Pulmonary hypertension
Most Recent Events
- 30 Sep 2023 Aerami Therapeutics updated an open IND application with the US FDA for a phase II proof-of-concept trial in Pulmonary arterial hypertension
- 12 Sep 2023 Adverse events and pharmacokinetics data from a phase-I trial in Pulmonary arterial hypertension presented at the International Congress of European Respiratory Society (ERS-2023)
- 12 Sep 2023 Aerami Therapeutics plans phase-II uniPHied trial for pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (Inhalation)